204 related articles for article (PubMed ID: 11358814)
1. Identification of the transcriptional regulatory sequences of human calponin promoter and their use in targeting a conditionally replicating herpes vector to malignant human soft tissue and bone tumors.
Yamamura H; Hashio M; Noguchi M; Sugenoya Y; Osakada M; Hirano N; Sasaki Y; Yoden T; Awata N; Araki N; Tatsuta M; Miyatake SI; Takahashi K
Cancer Res; 2001 May; 61(10):3969-77. PubMed ID: 11358814
[TBL] [Abstract][Full Text] [Related]
2. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
Jacobs A; Tjuvajev JG; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson SM; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO; Blasberg RG
Cancer Res; 2001 Apr; 61(7):2983-95. PubMed ID: 11306477
[TBL] [Abstract][Full Text] [Related]
3. Effective treatment of tumors with strong beta-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector.
Kuroda T; Rabkin SD; Martuza RL
Cancer Res; 2006 Oct; 66(20):10127-35. PubMed ID: 17047077
[TBL] [Abstract][Full Text] [Related]
4. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
[TBL] [Abstract][Full Text] [Related]
5. Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant.
Mineta T; Rabkin SD; Martuza RL
Cancer Res; 1994 Aug; 54(15):3963-6. PubMed ID: 8033122
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon.
Akbulut H; Zhang L; Tang Y; Deisseroth A
Cancer Gene Ther; 2003 May; 10(5):388-95. PubMed ID: 12719708
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic recombinant herpes simplex virus for treatment of orthotopic liver tumors in nude mice.
Chung YS; Miyatake S; Miyamoto A; Miyamoto Y; Dohi T; Tanigawa N
Int J Oncol; 2006 Apr; 28(4):793-8. PubMed ID: 16525626
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis.
Li X; Jung C; Liu YH; Bae KH; Zhang YP; Zhang HJ; Vanderputten D; Jeng MH; Gardner TA; Kao C
J Gene Med; 2006 Jun; 8(6):679-89. PubMed ID: 16570242
[TBL] [Abstract][Full Text] [Related]
9. Hepatoma-specific antitumor activity of an albumin enhancer/promoter regulated herpes simplex virus in vivo.
Miyatake SI; Tani S; Feigenbaum F; Sundaresan P; Toda H; Narumi O; Kikuchi H; Hashimoto N; Hangai M; Martuza RL; Rabkin SD
Gene Ther; 1999 Apr; 6(4):564-72. PubMed ID: 10476216
[TBL] [Abstract][Full Text] [Related]
10. Aberrant methylation and silencing of the calponin gene in human sarcoma cells.
Yamamura H; Yoshikawa H; Takahashi K
Anticancer Res; 2003; 23(1A):107-14. PubMed ID: 12680201
[TBL] [Abstract][Full Text] [Related]
11. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR
Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637
[TBL] [Abstract][Full Text] [Related]
12. A strict-late viral promoter is a strong tumor-specific promoter in the context of an oncolytic herpes simplex virus.
Fu X; Meng F; Tao L; Jin A; Zhang X
Gene Ther; 2003 Aug; 10(17):1458-64. PubMed ID: 12900760
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of hepatocellular carcinoma with a novel gene-viral therapeutic system CNHK300-murine endostatin].
Li GC; Nie MM; Yang JM; Su CQ; Sun LC; Qian YZ; Sham J; Fang GE; Wu MC; Qian QJ
Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(11):943-8. PubMed ID: 15329284
[TBL] [Abstract][Full Text] [Related]
14. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
[TBL] [Abstract][Full Text] [Related]
15. Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter.
Komata T; Kondo Y; Kanzawa T; Hirohata S; Koga S; Sumiyoshi H; Srinivasula SM; Barna BP; Germano IM; Takakura M; Inoue M; Alnemri ES; Shay JW; Kyo S; Kondo S
Cancer Res; 2001 Aug; 61(15):5796-802. PubMed ID: 11479218
[TBL] [Abstract][Full Text] [Related]
16. Calponin and h-caldesmon in soft tissue tumors: consistent h-caldesmon immunoreactivity in gastrointestinal stromal tumors indicates traits of smooth muscle differentiation.
Miettinen MM; Sarlomo-Rikala M; Kovatich AJ; Lasota J
Mod Pathol; 1999 Aug; 12(8):756-62. PubMed ID: 10463476
[TBL] [Abstract][Full Text] [Related]
17. Herpes simplex virus type 1 vector mediated gene transfer to muscle.
Huard J; Goins WF; Glorioso JC
Gene Ther; 1995 Aug; 2(6):385-92. PubMed ID: 7584113
[TBL] [Abstract][Full Text] [Related]
18. Trans-complementing adenoviral vectors for oncolytic therapy of malignant melanoma.
Wolkersdörfer GW; Morris JC; Ehninger G; Ramsey WJ
J Gene Med; 2004 Jun; 6(6):652-62. PubMed ID: 15170736
[TBL] [Abstract][Full Text] [Related]
19. [The efficacy of autocatalytic casapse-3 driven by human telomerase reverse transcriptase promoter on human ovarian carcinoma].
Song Y; Shen K; Yu JR
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(41):2919-24. PubMed ID: 18261307
[TBL] [Abstract][Full Text] [Related]
20. Cotargeting tumor and stroma in a novel chimeric tumor model involving the growth of both human prostate cancer and bone stromal cells.
Hsieh CL; Gardner TA; Miao L; Balian G; Chung LW
Cancer Gene Ther; 2004 Feb; 11(2):148-55. PubMed ID: 14695756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
